Literature DB >> 24505094

Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study.

Mayur Garg1, Louise M Burrell2, Elena Velkoska2, Karen Griggs2, Peter W Angus3, Peter R Gibson4, John S Lubel5.   

Abstract

INTRODUCTION: The relationship between intestinal inflammation and circulating components of the renin-angiotensin system (RAS) is poorly understood.
MATERIALS AND METHODS: Demographic and clinical data were obtained from healthy controls and patients with inflammatory bowel disease (IBD). Plasma concentrations of the classical RAS components (angiotensin-converting enzyme (ACE) and angiotensin II (Ang II)) and alternative RAS components (ACE2 and angiotensin (1-7) (Ang (1-7))) were analysed by radioimmuno- and enzymatic assays. Systemic inflammation was assessed using serum C-reactive protein (CRP), white cell count, platelet count and albumin, and intestinal inflammation by faecal calprotectin.
RESULTS: Nineteen healthy controls (11 female; mean age 38 years, range 23-68), 19 patients with Crohn's disease (11 female; aged 45 years, range 23-76) and 15 patients with ulcerative colitis (6 female; aged 42 years, 26-64) were studied. Circulating classical RAS component levels were similar across the three groups, whereas ACE2 activity and Ang (1-7) concentrations were higher in patients with IBD compared to controls (ACE2: 21.5 vs 13.3 pmol/ml/min, p<0.05; Ang (1-7): 22.8 vs 14.1 pg/ml, p<0.001). Ang (1-7) correlated weakly with platelet and white cell counts, but not calprotectin or CRP, in patients with IBD.
CONCLUSIONS: Circulating components of the alternative RAS are increased in patients with IBD.
© The Author(s) 2014.

Entities:  

Keywords:  Crohn’s disease; Renin-angiotensin system; angiotensin (1–7); angiotensin II; angiotensin-converting enzyme; angiotensin-converting enzyme 2; inflammatory bowel disease; ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 24505094     DOI: 10.1177/1470320314521086

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  35 in total

1.  Angiotensin II inhibits P-glycoprotein in intestinal epithelial cells.

Authors:  Anoop Kumar; Shubha Priyamvada; Vikas Soni; Arivarasu N Anbazhagan; Tarunmeet Gujral; Ravinder K Gill; Waddah A Alrefai; Pradeep K Dudeja; Seema Saksena
Journal:  Acta Physiol (Oxf)       Date:  2019-07-01       Impact factor: 6.311

Review 2.  Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.

Authors:  Shuvra Ray; Carlo De Salvo; Theresa T Pizarro
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

Review 3.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

4.  Impact of COVID-19 on Patients with Inflammatory Bowel Disease.

Authors:  Paula A Ambrose; Wendy A Goodman
Journal:  J Explor Res Pharmacol       Date:  2021-10-12

5.  Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis.

Authors:  Maitham A Khajah; Maryam M Fateel; Kethireddy V Ananthalakshmi; Yunus A Luqmani
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

6.  Under control: how a dietary additive can restore the gut microbiome and proteomic profile, and improve disease resilience in a marine teleostean fish fed vegetable diets.

Authors:  María Carla Piazzon; Josep Alvar Calduch-Giner; Belén Fouz; Itziar Estensoro; Paula Simó-Mirabet; Mónica Puyalto; Vasileios Karalazos; Oswaldo Palenzuela; Ariadna Sitjà-Bobadilla; Jaume Pérez-Sánchez
Journal:  Microbiome       Date:  2017-12-28       Impact factor: 14.650

Review 7.  Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?

Authors:  Armando Rojas; Iván Schneider; Cristian Lindner; Ileana Gonzàlez; Miguel Angel Morales
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

Review 8.  Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.

Authors:  Marko Kumric; Tina Ticinovic Kurir; Dinko Martinovic; Piero Marin Zivkovic; Josko Bozic
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

9.  Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome.

Authors:  Sonia Pellissier; Cécile Dantzer; Laurie Mondillon; Candice Trocme; Anne-Sophie Gauchez; Véronique Ducros; Nicolas Mathieu; Bertrand Toussaint; Alicia Fournier; Frédéric Canini; Bruno Bonaz
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

10.  AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease.

Authors:  Tian-Jing Liu; Yong-Yan Shi; En-Bo Wang; Tong Zhu; Qun Zhao
Journal:  Mol Med Rep       Date:  2015-12-14       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.